Tuberculosis (TB) infection treatment comprises of 4 drug regimen isoniazid, rifampin, pyrazinamide, and either ethambutol or streptomycin to sterile or kill the Mycobacterium bacteria. First line TB drugs are Isoniazid, Pyrazinamide, Ethambutol, Rifampicin. In second line of therapy, the drug combination varies as well as the drug dosage is increased because of resistance developed by the bacteria during first line of therapy. Patients undergo retreatment should be referred for a rapid molecular test or drug susceptibility testing to determine at rifampicin resistance importantly isoniazid resistance. According to WHO, in 2016, around 1.3 million deaths were reported among HIV negative people, additionally, 374,000 deaths were reported in HIV Positive people. In 2016, 10.4 million people fell ill among them 90% were adults and 65% were male. Due to this increasing number of tuberculosis and increasing awareness among people drive the tuberculosis drug market.
The global tuberculosis drugs market can be segmented by disease type and therapy. On the basis of disease type, the tuberculosis drugs market can be segmented into active TB and latent TB. Among the two, the latent TB segment is expected to dominate the market during the forecast period. Based on therapy, the market can be segmented into first-line therapy and second-line therapy.
Geographically, the tuberculosis drugs market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (LAMEA).
North America is expected to account for the largest share in the global tuberculosis drugs market due to the increasing prevalence of tuberculosis among babies and the geriatric population on account of weak immune systems. Europe accounts for a significant share of the global tuberculosis drugs market, driven by the increasing prevalence of tuberculosis in the U.K. As per of Public Health England (PHE), in 2017, the incidence rate of TB in England is 9.2 per 100,000 population and there is 9% decrease in the diagnosis of TB between 2016 and 2017 alone.
Asia-Pacific is pegged to be the fastest growing market during the forecast period, owing to the increasing incidences of Multidrug-Resistant (MDR) tuberculosis and HIV-tuberculosis co-infection in the region. The LAMEA region is expected to witness substantial growth in the global market during the forecast period, owing to the increasing prevalence of tuberculosis drugs in the region.
Key players in the tuberculosis drugs market include Sigma Pharmaceutical Pty Limited, Aventis Pharmaceuticals Limited, Novartis AG, Sanofi, Aventis U.S LLC, Hoffmann-La Roche Ltd, Versapharma Incorporated, and Bayer HealthCare.